James Moore: Deals look better for the prey than the predator
Outlook AstraZeneca and Yahoo could be corporate twins. They operate in very different sectors but the problems facing both are remarkably similar, and so are the drugs their respective chief executives have settled upon to treat what ails them.
Both are big, wealthy, cash rich, businesses facing flat or declining revenues while struggling to find replacements for products which are losing either patent protection, or relevance, or both.
Both are now hoping that they can buy their way out of their difficulties. That means paying vastly over the odds for companies which have potential but not much beyond that.
Yahoo's recent acquisition of Tumblr, the blogging site which has a popular product but which doesn't make much out of it, is very much in that category.
Meanwhile Astra, which has been doing much the same thing with a string of biotechnology acquisitions, added to its number yesterday with Omthera Pharmaceuticals, whose speciality is fish oil-derived heart medicines.
Its lead drug has at least completed the final stage of its trials, although it still has to secure final US regulatory approvals, but this is hardly new news.
Even after the announcement of the successful trials, the market valued the company at significantly less than Astra paid for it. The purchase price represents an 88 per cent premium to Omthera's Friday close on the Nasdaq.
It's true that heart drugs are a speciality of AstraZeneca and Omthera's product could be combined with the former's cholesterol treatment Crestor. But, as with Yahoo it's very much could, might, if, maybe. And even if the products of their new playthings are winners, both these giants have to prove they can successfully exploit them. Big companies that buy smaller companies, even in industries that put a premium on innovation like the internet or pharmaceuticals, sometimes struggle to do that.
Their shareholders have to hope that their respective spending binges yield a winner or two, because so far the deals they've done look much better for the prey than the predator – prey that could easily be selling snake oil, rather than fish oil, when it comes to making a return for the predator's shareholders.
- 1 Nigel Farage: Me vs Russell Brand on Question Time – he's got the chest hair but where are his ideas?
- 2 Harry Potter fans can apply to the Hogwarts-inspired College of Wizardry
- 3 Jessica Chambers: 19-year-old woman 'doused with lighter fluid and burned alive' in the US
- 4 Russell Brand calls Nigel Farage 'poundshop Enoch Powell' in BBC Question Time debate
- 5 Orange Wednesdays are no more
Weather bomb in pictures: Storms cuts power for tens of thousands – and snow is on the way
Jessica Chambers: 19-year-old woman 'doused with lighter fluid and burned alive' in the US
Russell Brand calls Nigel Farage 'poundshop Enoch Powell' in BBC Question Time debate
Russell Brand was rendered speechless on Question Time by this man
Fury at Airbus after it hints the super-jumbo may be mothballed
Disgruntled RBS worker writes hilarious open letter to Russell Brand after anti-capitalist publicity stunt leaves him hungry
Shock poll shows voters believe Ukip is to the left of the Tories
Nigel Farage's approval rating hits 'record low' as popularity suffers in wake of Ukip sex scandal
Nigel Farage defends Kerry Smith 'ch***y' comment: 'If you are going for a Chinese, what do you say you’re going for?'
Ukip candidate jokes about 'shooting peasants' in racist and homophobic rant
Pakistan school attack live: Taliban kill at least 132 children in 'horrifying' massacre
iJobs Money & Business
$200 - $350 per annum: Carlton Senior Appointments: Managing Producer Office...
$125 - $225 per annum: Carlton Senior Appointments: San Fran - Investment Advi...
Up to £70,000 per annum + benefits: Sheridan Maine: Are you a qualified accoun...
Up to £65,000 per annum + benefits: Sheridan Maine: Are you a qualified accoun...